Listerine, Tylenol Push J&J Consumer Health To 2020 Finish Line Against Pandemic Weight
Executive Summary
Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.
You may also be interested in...
J&J CEO: COVID-19 ‘Demonstrated Importance of Self-Care Overall’
During JP Morgan conference, Alex Gorsky suggests responding to pandemic is changing health care, including businesses providing pharmaceuticals, medical technologies, nutritionals and other necessary products.
Band-Aid Covers Sales Driver Role To Continue J&J’s Consumer Health Business Growth
Iconic brand could have spurred consumer interest and helped drive 15.2% US sales growth for its wound care business with the launch earlier in 2020 of strips in hues that better match the skin tones of black and brown customers.
J&J International Baby, Beauty Lines Could Lead Trimming 10% Of Consumer Portfolio
J&J plans to cut 10% of its consumer health portfolio, with most divestitures in the baby and beauty care segments outside the US. It plans to focus on growing “stronghold” categories of skin health and self care, including Aveeno and Tylenol.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: